Graduated from Milan University, PhD from Southampton University, Paolo Lombardi has over 40yr experience in the pharmaceutical industrial setting and backgrounds in organic synthetic chemistry, process research chemistry, and therapeutic chemistry. He held growing positions in Farmitalia Carlo Erba R&D where he achieved the goal of discovering Exemestane, launched in the global market under the name Aromasin™ for breast cancer therapy, and the clinical follow-up candidate Minamestane, as well as provinding the relative manufacturing chemical technology. As Vice-president for Chemistry in Menarini Ricerche, Paolo fostered the discovery of Sabarubicin, a 3rd generation antitumour anthracycline presently in advanced clinical studies. He acted as a consultant for the pharmacompany IBI G.Lorenzini and the French start up biotech Chrysalon. Presently scientist-entrepreneur, co-founder and co-owner of Naxospharma Ltd., a drug discovery oriented small company. Inventor of over 70 patents in Therapeutic and Process Chemistry, author and co-author of over 150 research papers, reviews, abstracts, invited lectures and seminars. Teaching appointments at Universities, Master courses & Specialist Schools. Member of several scientific societies.